RAD51 and neoplasm: One XB type tumour (YOPC31) had mutations in the DNA damage pathway (RAD50, RAD51, BLM and BRD7), with the highest mutational burden (6.24 mutations/Mb), but the TIDE score of this tumour indicated lower responsiveness to anti-PD-1/PD-L1 therapy.